GANX - Company ID 0001819411
The table below shows Gain Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | $55.18K | $140.11K | $164.99K | $28.88K |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $10.21M | $10.79M | $11.52M | $8.38M | $7.16M | $2.26M |
| SG&A |
Gain Therapeutics, Inc. reported annual revenue of $55.18K for fiscal year 2023. That is down 60.6% from $140.11K in fiscal 2022. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $8.50M |
| $9.56M |
| $10.79M |
| $9.54M |
| $6.83M |
| $1.25M |
| Operating income | -$18.71M | -$20.35M | -$22.25M | -$17.78M | -$13.83M | -$3.48M |
| Income tax | $861.12K | $536.82K | $79.28K | $92.98K | $4.01K | $5.39K |
| Net income | -$20.16M | -$20.41M | -$22.27M | -$17.59M | -$13.89M | -$3.58M |
| EPS (diluted) | -$0.61 | -$0.89 | -$1.71 | -$1.48 | -$1.37 | -$1.33 |